Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Prevail Therapeutics Inc (PRVL) USD0.0001

Sell:$10.44 Buy:$10.50 Change: $0.03 (0.29%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Change: $0.03 (0.29%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
Change: $0.03 (0.29%)
Market closed |  Prices as at close on 4 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Prevail Therapeutics Inc. is a gene therapy company. The Company is developing and commercializing adeno-associated virus (AAV)-based gene therapies for patients with neurodegenerative diseases. It is engaged in applying a precision medicine approach to neurodegeneration by studying its gene therapies in genetically defined patient populations. The Company’s lead program is PR001 for the treatment of Parkinson’s disease with gaucher disease mutation, and neuronopathic gaucher disease. The Company is focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation and PR004 for the treatment of synucleinopathies.

Contact details

430 E 29th St Ste 940
United States
+1 (917) 3369310

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$359.93 million
Shares in issue:
34.25 million
United States
US dollar

Key personnel

  • Francois Nader
    Independent Chairman of the Board
  • Asa Abeliovich
    President, Chief Executive Officer, Director
  • Brett Kaplan
    Chief Financial Officer
  • Yong Dai
    Chief Technology Officer
  • Kira Schwartz
    General Counsel
  • Franz Hefti
    Chief Development Officer
  • Emily Minkow
    Chief Business Officer
  • Jeffrey Sevigny
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.